New Fixed-Dose Combination Pill: Dolutegravir + Abacavir + Lamivudine

Publish Date: 
Friday, September 26, 2014
The FDA has approved the coformulation of the integrase inhibitor dolutegravir (50 mg) with the NRTIs abacavir (600 mg) and lamivudine (300 mg); its brand name is Triumeq. Triumeq is the first single-pill combination that does not include tenofovir.

Project B.R.I.E.F – An Educational Video Intervention for HIV Prevention

Publish Date: 
Wednesday, September 10, 2014

Project B.R.I.E.F. (Behavior intervention, Rapid HIV test, Innovative video, Efficient cost and health care savings, and Facilitated seamless linkage to outpatient HIV care) began in 2003 as a collaboration between two physicians looking to make a difference in the Bronx, NY community. As attending physicians at Jacobi Medical Center, both Dr. Jason Leider and I experienced first-hand the impact of HIV on the Bronx, a community with one of the highest rates of HIV prevalence in the nation.

HIV Meds Updates: Fast Takes - ATV & Rilpivirine / Rifabutin

Publish Date: 
Friday, August 1, 2014

ATV pediatric powder formulation

An oral powder formulation of atazanavir has been approved by the FDA for use in infants and children older than 3 months and weighing 10 to <25 kg. It must administered with ritonavir, and used in combination with other antiretrovirals. For infants, it may be mixed with formula (or other liquid) and given with an oral syringe or cup. For older infants and young children, it may be mixed with yogurt or applesauce.

Drug Interactions: Integrase Inhibitors and Cations

Publish Date: 
Friday, August 1, 2014

Antacids, laxatives, mineral supplements, and other compounds that contain metal cations (eg, calcium, magnesium, aluminum, and iron) may decrease levels of integrase inhibitors if taken close in time to each other. Results of two studies help to assess the magnitude of this effect and assist in determining how to manage it.

Efavirenz Updates: Bone Mineral Density & Suicidality

Publish Date: 
Friday, August 1, 2014

Efavirenz and Bone Mineral Density

Persons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (eg, tenofovir, protease inhibitors) cause greater losses over time than do others. It also is becoming clearer that vitamin D deficiency or insufficiency is common among HIV-infected persons, and that efavirenz can further lower levels of vitamin D.

Inside the New England AETC HIV Consultation Preceptorship Program: 2014

Publish Date: 
Friday, August 8, 2014

The New England AIDS Education and Training Center (NEAETC) has provided opportunities for physicians and nurses to hone their HIV skills for over 27 years. The HIV epidemic now seems to take a backseat to other trending health related crises in the US; Hepatitis C and Opioid overdoses to name two and yet we continue to receive applications from those looking for a chance to learn HIV practice in some world class institutions of Infectious Disease (ID) care.

New Initiatives and Updates from the United States-Mexico Border Binational Infectious Diseases Conference

Publish Date: 
Wednesday, July 16, 2014
I was honored to represent the Texas/Oklahoma AIDS Education and Training Center (AETC) and the U.S.-Mexico Border AETC Steering Teem (UMBAST) this year at the United States – Mexico Border Binational Infectious Disease Conference in El Paso, Texas. This binational meeting is convened each year by the United USMBHC States – Mexico Border Health Commission (BHC) in collaboration with other federal and state agencies.

Mortality Associated with Chronic Comorbidities among HIV-infected Persons in the United States

Publish Date: 
Wednesday, June 18, 2014

Combination antiretroviral therapy (cART) has substantially reduced HIV-related morbidity and mortality in the United States. HIV-infected persons today are living healthier and longer lives with expected lifespans near equal to those of uninfected person if the infection is effectively treated [1]. CDC estimates that by year 2020, over half of the HIV-infected persons in the United States will be aged 50 years or older [2].

Mental Health Awareness: How Aware Are We?

Publish Date: 
Wednesday, June 4, 2014

May was Mental Health Awareness month.  How aware of mental health issues are we in our own lives as well as in those we treat every day?  As HIV care providers, how often do we hear “I am so down,”  “I haven’t had fun in so long,” or “I’m so stressed.”  Often in our patient’s lives everything becomes a problem, so do we truly recognize the stress they may be experiencing?  With clinic visits becoming shorter and patient volume growing larger, checking in on a person’s mood often falls by the wayside. 


Subscribe to Sharespot RSS feed